

## Special Issue

# Molecular Advances in Diffuse Large B-Cell Lymphoma

### Message from the Guest Editors

Diffuse large B-cell lymphomas are heterogeneous aggressive lymphomas whose molecular background is still poorly understood. They are biologically and clinically different based on age (children, adults, elderly) of onset, place of development (nodal vs. extranodal), viral relationship, and immunosurveillance. Moreover, genetic subgroups have also been identified, such as high grade B-cell lymphomas with double or triple *MYC/BCL2/BCL6* gene rearrangements, 11q Burkitt-like lymphoma, *IRF4* translocated, or *ALK* translocated lymphomas, among others. We are proposing an extended review of new molecular advances in diffuse large B-cell lymphomas, taking into account all these previous features. Moreover, we highlight the existence of new approaches for high-grade B-cell lymphoma identification.

### Guest Editors

Dr. Socorro María Rodríguez-Pinilla

Dr. Arantza Onaindia

Dr. Paola A. Chabay

Dr. Fina Climent

### Deadline for manuscript submissions

closed (31 December 2021)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/63508](https://mdpi.com/si/63508)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)